AKBC member Patheon, by Thermo Fisher Scientific to help develop PharmAbcine Inc’s anti-tumour drug

AKBC member Patheon, by Thermo Fisher Scientific has entered into a strategic partnership with PharmAbcine Inc, a Korean biotech company. PharmAbcine will benefit from Thermo Fisher Scientific’s leading drug development and manufacturing capabilities including their Quick to Clinic™ integrated service offering. Thermo Fisher Scientific will help PharmAbcine progress the development of their drug, PMC-309, and its application for phase 1 clinical trials. PMC-309 is an antibody involved in inhibiting the activity of immune suppressor cells which are implicated in tumour formation.

Dr. Jin-San Yoo, CEO of PharmAbcine, remarked, “we are excited about the progress we have made with PMC-309 and strongly believe that PMC-309 will fulfill the gap in immune-oncology drug landscape.”

PharmAbcine aims to submit their phase 1 application in 2021.

Click here to read more.

Photo credit:

AKBC Membership

AKBC welcomes new members from both the Australian and Korean business community.

Join now

What’s on

AKBC runs events on a regular basis to keep members informed about the latest developments in Australia-Korea trade and investment.

See events

AKBC Newsletter

AKBC issues a monthly newsletter about the latest trends and developments in the Australia-Korea relationship. Sign up to our free e-newsletter by entering your email below.

Australia Korea Business Council
PO Box 24430
Melbourne, Vic 3001 Australia
Liz Griffin – Executive Director

The Australia-Korea Business Council is the leading national body committed to strengthening the Australia-Korea economic relationship.